Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Purdue Pharma: From Blockbuster Success To Bankrupt Villain

Sep 16 2019

• By Jessica Merrill

Bankruptcy Closeup Concept. American Dollars Cash Money,3D rendering. Bankruptcy at Dollar Banknote. Financial USA money banknote Commercial money investment profit concept - Illustration — Purdue Pharma filed for bankruptcy, a landmark moment in the opioid liability crisis • Source: Shutterstock

Related Content

OxyContin Revised Labeling Expects Less Abuse Via Injection, Snorting

Apr 17 2013

Will Purdue Bankruptcy Filing Resolve 'Unrelenting Chaos' Of Opioid Litigation?

Sep 16 2019

Insys Must Divest Subsys, Buprenorphine Candidate Products As Part Of Corporate Integrity Agreement

Jun 07 2019

Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims

Mar 24 2014

Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.

May 14 2007

Purdue Nears Settlement Of Opioid Multidistrict Litigation, But State AGs Vow To Press On

Sep 12 2019

Opioid Exposure Risk Intensifying For Generic Drug Makers

Aug 08 2019

Related Companies

Purdue Pharma L.P.

Johnson & Johnson

Teva Pharmaceutical Industries Ltd.

Mallinckrodt plc

Endo, Inc.

INSYS Therapeutics, Inc.

Pfizer Inc.

Merck & Co., Inc.

Additional Topics

Legal Issues Companies Drug Safety Commercial BioPharmaceutical

More from Legal & IP

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.